0001193125-22-025229.txt : 20220202 0001193125-22-025229.hdr.sgml : 20220202 20220202080102 ACCESSION NUMBER: 0001193125-22-025229 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220202 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220202 DATE AS OF CHANGE: 20220202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 22581594 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 d285349d8k.htm 8-K 8-K
AMEDISYS INC false 0000896262 0000896262 2022-02-02 2022-02-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2022

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   11-3131700
(State or other jurisdiction of
incorporation or organization)
  (IRS Employer
Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   AMED   The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


SECTION 7 - REGULATION FD

 

Item 7.01.

Regulation FD Disclosure.

On February 2, 2022, Amedisys, Inc. (the “Company”) issued a press release announcing that it has signed a definitive agreement to acquire Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release dated February 2, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.
By:  

/s/ Paul B. Kusserow

Paul B. Kusserow
Chief Executive Officer and Chairman of the Board
DATE: February 2, 2022
EX-99.1 2 d285349dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Amedisys Signs Definitive Agreement to Acquire

Evolution Health

BATON ROUGE, La., February 2, 2022 (GLOBE NEWSWIRE) – Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, announced today that it has signed a definitive agreement to acquire Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati. Headquartered in Dallas, Texas, the company cares for more than 3,300 home health patients daily and employs more than 650 employees in 15 locations across Texas, Oklahoma and Ohio.

Under the terms of the transaction, expected to close in the first half of 2022, Amedisys will acquire 100 percent of the ownership interests in Evolution Health. Once complete, this will increase Amedisys’ home health access to more than 1.9 million Medicare enrollees and more than 690,000 Medicare Advantage enrollees in Texas, and more than 800,000 Medicare enrollees and more than 350,000 Medicare Advantage enrollees in Ohio. Post-closing, Amedisys will provide both home health and hospice services to six communities across Texas, including Dallas/Fort Worth, San Antonio and Houston, furthering our strategy to become the solution for those who want to age in place.

“By continuing the great care provided by Evolution Health, Amedisys will provide additional scale and resources that will expand our opportunities to care for more patients and in more communities across Texas, Oklahoma and Ohio,” said Amedisys President and Chief Operating Officer Chris Gerard. “Amedisys is proud to expand its presence in these healthcare communities and provide more comprehensive care by aligning with our Amedisys Hospice footprint in Texas.”

“The purchase of Evolution Health continues our strategy to acquire and integrate high-quality regional home health assets into our home health division, which leads the industry in quality,” said Amedisys Chairman and Chief Executive Officer Paul Kusserow.

The transaction adds greater scale to Amedisys’ high-quality, nationwide network of 331 home health care centers. Post-closing, the combined home health operations will include 346 care centers in 34 states and the District of Columbia, with an average daily census of approximately 73,499 patients and approximately 11,236 home health employees.

“Both Evolution Health and Amedisys share a commitment to providing quality care to our patients in the comfort of their homes,” said Evolution Health President Mike Parsons. “We look forward to growing with Amedisys and continuing to offer our employees exceptional resources and support to care for their patients, along with access to expanded service offerings.”


In 2021, Modern Healthcare named Amedisys, Inc. to its prestigious Best Places to Work in Healthcare list. Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States with 528 locations across 38 states and the District of Columbia. As of the January 2022 Home Health Compare release, Amedisys’ Quality of Patient Care (QPC) Star score is 4.33. The Company also provides personal care, palliative care and high-acuity care.

 

Media Contact:

  

Investor Contact:

Kendra Kimmons    Nick Muscato
Vice President of Marketing & Communications    Vice President of Strategic Finance
225-299-3708    615-928-5452
kendra.kimmons@amedisys.com    nick.muscato@amedisys.com

About Evolution Health

Evolution Health is a home health company headquartered in Dallas, Texas, serving three states through its family of trusted local brands. Working in partnership with the patient’s physician, Evolution Health offers traditional home health services reimbursed by Medicare, Medicaid and commercial payers including skilled nursing, occupational, physical and speech therapy, counseling and emotional support. Evolution Health’s highest priority is to provide quality, compassionate care to its patients, their families, and the communities in which they serve. For more information, visit https://www.evolution.net/.

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 528 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.

Forward-Looking Statements:

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the


Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

#    #    #

EX-101.SCH 3 amed-20220202.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 amed-20220202_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 amed-20220202_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g285349g0201082236924.jpg GRAPHIC begin 644 g285349g0201082236924.jpg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end GRAPHIC 7 g285349g0202054655822.jpg GRAPHIC begin 644 g285349g0202054655822.jpg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htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 02, 2022
Cover [Abstract]  
Entity Registrant Name AMEDISYS INC
Amendment Flag false
Entity Central Index Key 0000896262
Document Type 8-K
Document Period End Date Feb. 02, 2022
Entity File Number 0-24260
Entity Incorporation State Country Code DE
Entity Tax Identification Number 11-3131700
Entity Address, Address Line One 3854 American Way
Entity Address, Address Line Two Suite A
Entity Address, City or Town Baton Rouge
Entity Address, State or Province LA
Entity Address, Postal Zip Code 70816
City Area Code (225) 292-2031 or (800)
Local Phone Number 467-2662
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol AMED
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d285349d8k_htm.xml IDEA: XBRL DOCUMENT 0000896262 2022-02-02 2022-02-02 AMEDISYS INC false 0000896262 8-K 2022-02-02 0-24260 DE 11-3131700 3854 American Way Suite A Baton Rouge LA 70816 (225) 292-2031 or (800) 467-2662 false false false false Common Stock, par value $0.001 per share AMED NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d285349d8k.htm amed-20220202.xsd amed-20220202_lab.xml amed-20220202_pre.xml d285349dex991.htm g285349g0201082236924.jpg http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d285349d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d285349d8k.htm" ] }, "labelLink": { "local": [ "amed-20220202_lab.xml" ] }, "presentationLink": { "local": [ "amed-20220202_pre.xml" ] }, "schema": { "local": [ "amed-20220202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "amed", "nsuri": "http://www.amedisys.com/20220202", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d285349d8k.htm", "contextRef": "duration_2022-02-02_to_2022-02-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d285349d8k.htm", "contextRef": "duration_2022-02-02_to_2022-02-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001193125-22-025229-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-025229-xbrl.zip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